TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

Luca Gianni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.